EFG Asset Management Americas Corp. Has $2.50 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

EFG Asset Management Americas Corp. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,037 shares of the company's stock after selling 4,951 shares during the period. EFG Asset Management Americas Corp.'s holdings in IDEXX Laboratories were worth $2,496,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of IDXX. Insight Wealth Strategies LLC raised its holdings in shares of IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares during the period. Larson Financial Group LLC raised its holdings in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares during the period. Quest Partners LLC raised its holdings in shares of IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company's stock valued at $1,450,000 after purchasing an additional 2,801 shares during the period. Crystal Rock Capital Management raised its holdings in shares of IDEXX Laboratories by 90.0% in the 3rd quarter. Crystal Rock Capital Management now owns 9,005 shares of the company's stock valued at $4,550,000 after purchasing an additional 4,265 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of IDEXX Laboratories by 3.4% in the 3rd quarter. Victory Capital Management Inc. now owns 142,628 shares of the company's stock valued at $72,059,000 after purchasing an additional 4,696 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX traded up $1.09 on Friday, reaching $430.12. 654,250 shares of the company's stock were exchanged, compared to its average volume of 542,991. The company has a fifty day moving average of $437.37 and a 200-day moving average of $449.41. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $562.25. The company has a market capitalization of $34.98 billion, a price-to-earnings ratio of 40.31, a PEG ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IDXX. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target on the stock. Finally, Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $533.75.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.